These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

198 related items for PubMed ID: 23269286

  • 1. Inhibition of cholesteryl ester transfer protein by anacetrapib does not impair the anti-inflammatory properties of high density lipoprotein.
    Han S, Levoci L, Fischer P, Wang SP, Gagen K, Chen Y, Xie D, Fisher T, Ehrhardt AG, Peier AM, Johns DG.
    Biochim Biophys Acta; 2013 Apr; 1831(4):825-33. PubMed ID: 23269286
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Anacetrapib and dalcetrapib differentially alters HDL metabolism and macrophage-to-feces reverse cholesterol transport at similar levels of CETP inhibition in hamsters.
    Briand F, Thieblemont Q, Muzotte E, Burr N, Urbain I, Sulpice T, Johns DG.
    Eur J Pharmacol; 2014 Oct 05; 740():135-43. PubMed ID: 25008069
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Cholesteryl ester transfer-protein modulator and inhibitors and their potential for the treatment of cardiovascular diseases.
    Shinkai H.
    Vasc Health Risk Manag; 2012 Oct 05; 8():323-31. PubMed ID: 22661899
    [Abstract] [Full Text] [Related]

  • 7. The Cholesteryl Ester Transfer Protein Inhibitor, des-Fluoro-Anacetrapib, Prevents Vein Bypass-induced Neointimal Hyperplasia in New Zealand White Rabbits.
    Wu BJ, Li Y, Ong KL, Sun Y, Johns D, Barter PJ, Rye KA.
    Sci Rep; 2019 Nov 07; 9(1):16183. PubMed ID: 31700015
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Effects of anacetrapib on plasma lipids in specific patient subgroups in the DEFINE (Determining the Efficacy and Tolerability of CETP INhibition with AnacEtrapib) trial.
    Brinton EA, Kher U, Shah S, Cannon CP, Davidson M, Gotto AM, Ashraf TB, McCrary Sisk C, Dansky H, Mitchel Y, Barter P, DEFINE Investigators.
    J Clin Lipidol; 2015 Nov 07; 9(1):65-71. PubMed ID: 25670362
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Effects of anacetrapib on plasma lipids, apolipoproteins and PCSK9 in healthy, lean rhesus macaques.
    Roddy TP, McLaren DG, Chen Y, Xie D, Dunn K, Kulick A, Szeto D, Forrest G, Albanese K, Donnelly M, Gai C, Gewain A, Lederman H, Jensen KK, Ai X, Vachal P, Akinsanya KO, Cleary MA, Previs SF, Dansky HM, Johns DG.
    Eur J Pharmacol; 2014 Oct 05; 740():410-6. PubMed ID: 24769414
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Different effects of compounds decreasing cholesteryl ester transfer protein activity on lipoprotein metabolism.
    Niesor EJ.
    Curr Opin Lipidol; 2011 Aug 05; 22(4):288-95. PubMed ID: 21587074
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Cholesterol efflux potential and antiinflammatory properties of high-density lipoprotein after treatment with niacin or anacetrapib.
    Yvan-Charvet L, Kling J, Pagler T, Li H, Hubbard B, Fisher T, Sparrow CP, Taggart AK, Tall AR.
    Arterioscler Thromb Vasc Biol; 2010 Jul 05; 30(7):1430-8. PubMed ID: 20448206
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Anacetrapib: hope for CETP inhibitors?
    Gurfinkel R, Joy TR.
    Cardiovasc Ther; 2011 Oct 05; 29(5):327-39. PubMed ID: 20406242
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.